Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study.
about
Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease.Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study.Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
P2860
Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Treatment with oral paricalcit ...... tage 3-4: a preliminary study.
@ast
Treatment with oral paricalcit ...... tage 3-4: a preliminary study.
@en
type
label
Treatment with oral paricalcit ...... tage 3-4: a preliminary study.
@ast
Treatment with oral paricalcit ...... tage 3-4: a preliminary study.
@en
prefLabel
Treatment with oral paricalcit ...... tage 3-4: a preliminary study.
@ast
Treatment with oral paricalcit ...... tage 3-4: a preliminary study.
@en
P2093
P2860
P356
P1476
Treatment with oral paricalcit ...... tage 3-4: a preliminary study.
@en
P2093
Dimitrios Hadjiyannakos
Dimosthenis Vlassopoulos
Ioannis Karatzas
Konstantinos Panagiotopoulos
Makroui Sonikian
Sofia Trompouki
Vassilis Filiopoulos
P2860
P304
P356
10.1093/CKJ/SFS188
P577
2013-02-05T00:00:00Z